Abstract
Reports on three patients with malignant adrenal phaeochromocytoma are used as a basis for discussion of involved in diagnosing functionally inactive paragangliomas and in discriminating between benign and malignant adrenomedullary tumours. Malignancy can so far only be ascertained in such neoplasms by evidence of metastatic growth. Our findings, however, show that increased tumour weight (more than 200 g), high mitotic activity (more than 5 mitoses per HPF) and loss of S-100 protein-positive subtentacular cells make it possible to distinguish high-risk cases (with increased risk of recurrence and metastasis).
Zusammenfassung
Am Beispiel von 3 Patienten mit einem malignen adrenalen Phäochromozytom werden die Probleme bet der Diagnostik funktionell stummer Paragangliome und bei der Unterscheidung bösartiger von gutartigen Nebennierenmarktumoren diskutiert. Malignitätsbeweisend ist bislang lediglich der Nachweis metastatischen Geschwulstwachstums. Die eigenen Ergebnisse belegen jedoch, daß ein erhöhtes Tumorgewicht (> 200 g), eine gesteigerte Mitoserate (über 5 Kernteilungsfiguren pro 10 Tumorgesichtsfelder) Bowie der Verlust S-100-Protein-positiver Sustentakularzellen die Erkennung von Risikobefunden (mit hoher Rezidiv- und Metastasierungswahrscheinlichkeit) erlaubt.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Literatur
Achilles E, Padberg B, Holl K, Kldppel G, Schröder S (1991) Immunocytochemistry of paragangliomas-value of staining for S-100 protein and glial fibrillary acid protein in diagnosis and prognosis. Histopathology 18:453–458
Andersen GS, Toftdahl DB, Lund JO, Strangaard S, Nielsen PE (1988) The incidence rate of pheochromocytoma and Conn's syndrome in Denmark. J Hum Hypertens 3:187–189
Brennan MF, Kaiser HR (1982) Persistent and recurrent pheochromozytoma. World J Surg 6:397–402
Crout J, Pisano J, Sjoersdma A (1961) Urinary excretion of catecholamines and their metabolites in pheochromocytoma. Am Heart J 61:375–381
Endo K, Shiomi K, Kasagi K, Torizuka J (1984) Imaging of medullary carcinoma of the thyroid with 131-MIBG. Lancet 11:233
Fischer M, Kamanabroo D, Sonderkamp H (1984) Scintigraphic imaging of carcinoid tumors with 131I-MIBG (letter). Lancet 1:8395
Frier DT, Harrison TS, Donahaue SM (1973) Rigorous biochemical criteria for the diagnosis of pheochromocytoma. J Surg Res 14:177–180
Gitlow SE, Medlowitz SM, Hamilton CA (1970) The biochemical techniques for detecting and establishing the presence of a pheochromocytoma: A review of ten years experience. Am J Cardiol 26:270–279
Havlik RC, Cahow B, Kinder K (1988) Advances in the diagnosis and treatment of pheochromocytoma. Arch Surg 26:626–630
Helman LJ, Cohen PS, Averbuch SD, Cooper MJ, Kaiser HR, Israel MA (1989) Neuropeptide Y expression distinguishes malignant from benign pheochromocytoma. J Clin Oncol 11:1729–1735
Heerden JA van, Sizemore GW Carney JA, Grant CS, Remine WH, Sheps SG (1984) Surgical management of the adrenal glands in the multiple endocrine neoplasia type II syndrome, World J Surg 8:612–621
Hosaka Y, Rainwater L-M, Grant CS, Farrow GM, Heerden JA van, Lieber MM (1986) Pheochromocytoma: Nuclear desoxyribonucleic acid patterns studied by flow cytometry. Surgery 100:1003–1010
Jones DH, Reid JL, Hamilton CA, Allison JL (1980) The biochemical diagnosis, localisation and follow up of pheochromocytoma: The role of plasma and urinary catecholamine measurements. Q L Med 49:341–361
Kimming B, Brandeis WE, Eisenhur M (1984) Spezifische Szintigraphie des Neuroblastoms mit Met-jod-benzylguanidin. Nucl Compact 15:42–48
Padberg BC, Achilles E, Garbe E, Dralle H, Klöppel G, Schröder S (1990) Histologie, Immuncytochemie und DNA-Cytophotometrie des adrenalen Phäochromozytoms (PCC) — eine morphologische Untersuchung an 64 Turmoren. Verh Dtsch Ges Pathol 74:289–294
Padberg BC, Garbe E, Achilles E, Dralle H, Bressel M, Schöder S (1990) Adrenomedullary hyperplasia and phaeochromocytoma. DNA cytophotometric findings in 47 cases. Virchows Arch [A] 416:443–446
Rosai I (1989) Adrenal gland and other paraganglia In: Rosai I (ed) Ackerman's surgical pathology, 7th edn, vol 1. Mosby, St. Louis Toronto Washington/DC, pp 789–818
Saaman NA, Hickey R, Shutts P (1988) Diagnosis, localisation, and management of pheochromocytoma. Cancer 62:2451–2460
Shapiro B, Sisson JC, Lloyd R (1985) Iodine-131 metaiodobenzylguanidine for the locating of suspected pheochromocytoma: Experience in 400 cases. J Nucl Med 26:576–585
Sheldon G, Jiang NS, Kleen GG (1988) Diagnostic evaluation of pheochromocytoma. Endocrinal Metab Clin North Am 17:397–414
Stenström G, Ernest I, Tiskell L (1988) Long-term results in 64 patients operated for pheochromocytoma. Acta Med Scand 223:345–352
Thomas JL, Bernardino ME, Samaan NA, Hichey RC (1981) CT of pheochromocytoma. AIR Am J Roentgenol 137:1227–1231
Wieland DM, Wu JL, Brown LE,Manager LA (1980) Radiolabeled adrenergic neuronblocking agents: Adrenomedullary imaging with 131Iodobenzylguanidine. J Nucl Med 21:349–353
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Brückner, M., Padberg, B.C., Dürig, M. et al. Maligne adrenale Phäochromozytome — Probleme der klinischen Diagnostik und morphologischen Dignitätsbestimmung. Langenbecks Arch Chir 378, 37–40 (1993). https://doi.org/10.1007/BF00207993
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF00207993